Inogen Inc. reported a total revenue of $348.7 million for the fiscal year ending December 31, 2025, marking a 3.9% increase from $335.7 million in 2024. The growth was primarily driven by a 5.9% rise in sales revenue, which reached $295.3 million, attributed to increased demand in international markets. However, rental revenue decreased by 6.3% to $53.4 million, largely due to a higher mix of lower private-payor reimbursement rates and a reduction in the number of patients on service. The company sold approximately 189,400 oxygen systems in 2025, a significant increase from 157,500 units sold in the previous year.
Inogen's gross profit for the year was $154.3 million, slightly down from $154.7 million in 2024, resulting in a total gross margin percentage of 44.2%, compared to 46.1% the previous year. The decline in gross margin was attributed to customer mix and increased costs associated with semiconductor chips used in their portable oxygen concentrators. Operating expenses also saw a decrease, with research and development expenses falling by 10.2% to $19.4 million, while sales and marketing expenses decreased by 5.2% to $97.7 million. The company reported a net loss of $22.7 million, a 36.6% improvement from the $35.9 million loss in 2024.
Strategically, Inogen expanded its product offerings through the acquisition of Physio-Assist in September 2023, which introduced the Simeox airway clearance device to its portfolio. The company also launched the Aurora CPAP masks in the U.S. market in November 2025, further diversifying its respiratory health product line. Inogen's collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. has enhanced its innovation pipeline and broadened its distribution capabilities, particularly in the Asia-Pacific region.
As of December 31, 2025, Inogen employed 753 individuals globally, with a significant portion dedicated to sales, marketing, and clinical services. The company reported that approximately 39.8% of its total revenue was generated from international markets, reflecting its ongoing efforts to expand its global footprint. The outlook for Inogen remains cautiously optimistic, with management indicating that existing capital resources and projected cash flows from product sales and rentals should be sufficient to meet operational needs for at least the next 12 months.
Inogen's financial performance and strategic initiatives underscore its commitment to enhancing patient care through innovative respiratory solutions, despite facing challenges such as fluctuating reimbursement rates and competitive pressures in the healthcare market.
About Inogen Inc
Inogen, Inc. develops and markets portable oxygen concentrators and airway clearance devices for respiratory health. Its core products include the Inogen One and Rove systems for long-term oxygen therapy and the Simeox device for bronchiectasis treatment. Serving patients with COPD and other chronic respiratory conditions, the company emphasizes innovation, clinical evidence, and direct-to-consumer and provider sales channels to improve mobility and quality of life.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.